Glioblastoma U-87MG tumour cells suppressed by ZnO folic acid-conjugated nanoparticles: an in vitro study.
Glioblastoma Multiform (GBM) known as the most common CNS malignant tumour. Therapy for GBM includes maximum tumour resection and chemotherapy. Recent advances have emphasized the use of nanoparticles, such as zinc oxide nanoparticles (ZnO-NPs). Conjugated ZnO NPs with folic acid (FA) easily pass through cell membrane. In the present study, ZnO NPs-FA applied to GBM U87MG cell line. ZnO NPs-FA synthesized according to the sol-gel method. The GBM U87MG and astrocytes 1321N1 cell lines cultured and divided into control, sham and ZnO NPs-FA groups. MTT assay used for the cell viability, and ROS assay and flow cytometry exploited. The size of nanoparticles was ≤20 nm using TEM and FTIR. After 12 hours, the viability for U87MG cells showed a significant decrease at 1.25 and 2.5 mg/ml concentrations. However, no such results obtained for astrocytes. According to the results, the ROS assay caused a significant increase in GBM cells at the mentioned concentration. It was concluded that dose-dependent conjugated NPs could play a therapeutic role in cancer therapy.